OxFORD Asset Management LLP Purchases 25,252 Shares of INC Research Holdings, Inc. (INCR)
OxFORD Asset Management LLP increased its position in INC Research Holdings, Inc. (NASDAQ:INCR) by 45.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 81,398 shares of the company’s stock after purchasing an additional 25,252 shares during the period. OxFORD Asset Management LLP owned approximately 0.08% of INC Research worth $4,282,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Lee Thomas H Partners LP bought a new position in shares of INC Research in the 3rd quarter worth $1,316,644,000. BlackRock Inc. lifted its holdings in shares of INC Research by 82.3% in the 2nd quarter. BlackRock Inc. now owns 6,461,899 shares of the company’s stock worth $378,020,000 after purchasing an additional 2,917,605 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of INC Research by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 6,186,393 shares of the company’s stock worth $361,904,000 after purchasing an additional 142,349 shares in the last quarter. State Street Corp lifted its holdings in shares of INC Research by 112.8% in the 2nd quarter. State Street Corp now owns 1,769,353 shares of the company’s stock worth $103,508,000 after purchasing an additional 937,864 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new position in shares of INC Research in the 2nd quarter worth $99,424,000. Institutional investors own 99.56% of the company’s stock.
In other news, CEO Alistair Macdonald sold 2,348 shares of the firm’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $54.60, for a total transaction of $128,200.80. Following the completion of the sale, the chief executive officer now directly owns 99,453 shares of the company’s stock, valued at approximately $5,430,133.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Gregory S. Rush sold 9,703 shares of the firm’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $54.48, for a total value of $528,619.44. Following the sale, the chief financial officer now directly owns 78,593 shares of the company’s stock, valued at $4,281,746.64. The disclosure for this sale can be found here. Insiders sold a total of 16,733 shares of company stock valued at $912,270 over the last three months. 0.24% of the stock is currently owned by insiders.
Shares of INC Research Holdings, Inc. (NASDAQ:INCR) opened at $37.95 on Thursday. The company has a market capitalization of $4,030.00, a price-to-earnings ratio of 17.43, a P/E/G ratio of 1.20 and a beta of 1.08. INC Research Holdings, Inc. has a 12-month low of $33.60 and a 12-month high of $61.10. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.27 and a quick ratio of 1.27.
INC Research (NASDAQ:INCR) last released its quarterly earnings results on Thursday, November 9th. The company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.63 by ($0.09). The company had revenue of $592.21 million during the quarter, compared to analysts’ expectations of $604.95 million. INC Research had a negative net margin of 4.29% and a positive return on equity of 14.42%. The company’s quarterly revenue was up 128.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.64 earnings per share. equities analysts anticipate that INC Research Holdings, Inc. will post 2.15 earnings per share for the current fiscal year.
INC Research Profile
INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
Receive News & Ratings for INC Research Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.